11:00 AM – Welcome and Introduction
11:05 AM – Patient Case Studies with short didactic and panel discussions
- Case Discussion 1: Early Treatment for High-Risk Smoldering MM: Going for a Cure?
- Case Discussion 2: Individualized Approaches to Frontline Treatment Selection
- Case Discussion 3: Managing the Patient With Relapsed Disease After ≥ 1 Lines of Therapy
- Case Discussion 4: Understanding the Different Anti-BCMA Therapies
1:05 PM – Panel Discussion 5: Future Directions and Key Studies from ASH 2020
1:30 PM – New 2021 Treatment Algorithm for MM
1:50 PM – Final Thoughts
Date / Time
Brian G.M. Durie, MD
Medical Director, AMyC
Co-Chair Myeloma Committee, SWOG
Chairman, International Myeloma Foundation
Specialist in Multiple Myeloma and Related Disorders
Cedars-Sinai Outpatient Cancer Center
Los Angeles, California
Shaji Kumar, MD
Department of Hematology
Thomas G. Martin, MD
Clinical Professor of Medicine
Associate Director, Myeloma Program
University of California, San Francisco Medical Center
San Francisco, California
Philippe Moreau, MD
Professor of Clinical Hematology
Head, Hematology Department
University Hospital Hôtel-Dieu
S. Vincent Rajkumar, MD
Edward W. and Betty Knight Scripps
Professor of Medicine
Jesus San-Miguel, MD
Director of Clinical and Translational Medicine
Universidad de Navarra
The goal of this activity is to improve participants’ competence in and performance at applying practice-changing clinical data and expert recommendations to optimize the care of their patients with multiple myeloma.
This program is intended for physicians and other healthcare providers who care for patients with multiple myeloma.
Upon completion of this activity, participants should be able to:
- Initiate timely systemic treatment for appropriate patients based on the latest multiple myeloma diagnosis and staging criteria
- Plan individualized treatment strategies for patients with multiple myeloma through consideration of the available clinical data as well as risk assessment, comorbidities, and patient age/fitness and preferences
- Evaluate the efficacy and safety evidence of novel combination therapeutic regimens for patients with multiple myeloma
- Select optimal therapies for patients with heavily pretreated relapsed/refractory MM based on individual patient and disease characteristics
- Explain the mechanism of action of newer classes of agents indicated for and under investigation for myeloma
- Identify patients with relapsed/refractory MM who would be eligible for enrollment in late-phase clinical trials
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower, International Myeloma Foundation and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
Physician Continuing Medical Education
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.